成都市贝瑞和康基因技术股份有限公司 关于子公司对外投资的自愿性披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次子公司对外投资设立合资公司，首期注册资本100万元，主要用于场地租金 和初期人员费用，合资公司的产品及其相关服务（包含基因测序和AI智能体服务等）， 主要通过向成都市贝瑞和康基因技术股份有限公司及其下属主体采购获得。 2、合资公司将根据业务进展情况，通过注册资本增资等方式，扩充合资公司经营 资金。如合资公司未来经营情况符合各方预期，预计注册资本不低于5,000万元。 3、投资标的设立尚需注册地市场监督管理部门审批。 一、子公司对外投资概述 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-040 5、经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；计算机系统服务；信息技术咨询服务；软件开发；诊所服务（工商局注 册，市场监督管理局，卫健委）；健康咨询服务（不含诊疗服务）；仪器仪表销售；计 算机软硬件及辅助设备零售；人工智能硬件销售；专业设计服务；第一类医疗器械销 售；化工产品销 ...

Group 1 - The core point of the article is the establishment of a joint venture company, 河南壹元童康基因科技有限公司, by 贝瑞和康 and individual investor 李巍 in Zhengzhou, Henan Province [1] - The registered capital of the joint venture is set at 1 million yuan, with 贝瑞和康 contributing 600,000 yuan for a 60% stake, while 李巍 invests 400,000 yuan for a 40% stake [1] - The joint venture will focus on products and services including gene sequencing and AI intelligent services, primarily sourcing from 贝瑞基因 and its subsidiaries [1] Group 2 - The future capital of the joint venture is expected to reach no less than 50 million yuan if business operations meet expectations [1] - The establishment of the investment target is subject to approval from the local market supervision and administration department [1]

Group 1 - The article highlights the top 20 stocks with significant capital inflow as of August 7, with Lixun Precision leading at 447 million yuan [1] - Other notable stocks include Huasheng Tiancheng with 345 million yuan and Yingfangwei with 322 million yuan, indicating strong investor interest in these companies [1] - The list also features companies like GoerTek, Jishi Media, and Silan Microelectronics, each attracting over 200 million yuan in capital inflow, suggesting a trend in the technology and electronics sectors [1] Group 2 - The total capital inflow for the top 20 stocks amounts to significant sums, reflecting a robust market sentiment and potential investment opportunities [1] - Companies such as BYD and Yunda Holdings, with inflows of 137 million yuan each, indicate a diverse range of sectors attracting investor attention [1] - The data suggests a concentrated interest in technology and innovation-driven companies, which may signal future growth potential in these industries [1]

Core Viewpoint - The medical device sector is experiencing significant growth, driven by strong performance in the medical device ETF and favorable regulatory developments [1][3]. Group 1: Market Performance - The CSI All Share Medical Device Index (H30217) rose by 2.6%, with notable gains from stocks such as Sainuo Medical (688108), Zhonghong Medical (300981), and Lide Man (300289) [1]. - The medical device ETF (159883) increased by 2.67%, reaching a total share of 5.954 billion, making it the largest among comparable funds [1][2]. - In July, the ETF saw a net subscription of 112 million shares, with a total increase of 1.94 billion shares, marking a record high [1]. Group 2: Regulatory Developments - Recent measures from seven regulatory bodies aim to promote the high-quality development of commercial health insurance and the biopharmaceutical industry, enhancing the payment mechanisms for innovative medical devices [3]. - The National Medical Insurance Administration has emphasized support for genuine innovation in medical devices, rejecting superficial or redundant innovations [3]. Group 3: Pricing and Competition - The National Medical Insurance Administration has clarified that procurement will no longer solely focus on the lowest bid, requiring companies to justify their pricing, which may stabilize prices and profit margins in the medical device sector [4]. - The new procurement rules are expected to enhance the competitive advantage of leading companies with strong product performance and brand recognition [4]. Group 4: Key Holdings - As of June 30, 2025, the top ten weighted stocks in the CSI All Share Medical Device Index accounted for 46.92% of the index, with major players including Mindray Medical (300760) and United Imaging Healthcare (688271) [5].

Core Viewpoint - The company, Berry Genomics (000710), focuses on the reproductive health sector, achieving significant commercial effects in the prenatal testing market while the pre-pregnancy and newborn markets are still in the early stages, indicating substantial market potential [1] Group 1 - The company plans to expand its complex genetic testing services into more areas, leveraging artificial intelligence applications and years of experience in third-generation sequencing technology [1] - The company aims to provide more health services directly to the consumer (C-end) by integrating clinical medical data in the future [1] - The recent changes in major shareholder equity do not impact the company's business development [1]

贝瑞基因（000710.SZ）8月5日在投资者互动平台表示，公司业务一直聚焦生育健康领域，产前检测市 场已达成较好的商业效应，但在孕前和新生儿市场还处于起步阶段，市场空间较大。凭借人工智能应用 和公司积累多年的三代测序技术，公司将在更多领域开展复杂基因检测服务。同时，结合临床医疗数 据，后续公司计划将直接为C端群体提供更多健康服务。目前大股东股权变动不影响公司业务发展。 每经AI快讯，有投资者在投资者互动平台提问：董秘您好，公司信用减值损失连续几年上亿元，面对 主业持续亏损的情况下，请问公司如何解决当前困境，是否谋划扩展新业务来实现高质量发展？还有公 司大股东股权接连遭司法拍卖，公司有无应对措施，公司的控制权会不会发生变化？ （文章来源：每日经济新闻） ...

Group 1 - The assisted reproductive industry is experiencing a strong upward trend, with companies such as HanShang Group, FuYuan Pharmaceutical, and LiDeMan reaching their daily price limit [1] - Other companies in the sector, including GongTong Pharmaceutical, DaJia WeiKang, SiChuang YiHui, BoTuo Bio, BeiRui Gene, and MaiDi Technology, also saw significant increases in their stock prices [1]

Group 1 - The AI sector showed resilience in the market, with companies like Jin Modern (300830) and Zhi De Mai (300785) rising over 10% [1] - Other companies such as Youke De, San Liu Ling (601360), BlueFocus (300058), Berry Genomics (000710), and New Zhisoft also experienced upward movement [1]

A股辅助生殖板块持续走强，福元医药盘中创历史新高，共同药业、汉商集团、利德曼涨停，安科生物 涨超15%，广生堂涨超10%，新光药业、达嘉维康、贝因美、星昊医药、贝瑞基因跟涨。 ...

成都市贝瑞和康基因技术股份有限公司 上市公司名称：成都市贝瑞和康基因技术股份有限公司 股票上市地点：深圳证券交易所 股票简称：贝瑞基因 股票代码：000710 信息披露义务人一：高扬 住所及通讯地址：北京市昌平区科技园区生命园路4号院5号楼 邮政编码：102200 信息披露义务人二：侯颖 住所及通讯地址：北京市昌平区科技园区生命园路4号院5号楼 邮政编码：102200 股份变动性质：司法强制执行和司法拍卖导致触及信息披露义务 签署日期：2025年7月25日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式 准则第15号—权益变动报告书》及相关法律、法规及部门规章的有关规定编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反 信息披露义务人内部规则中的任何条款，或与之冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》及《公开发行证 券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报告书已 全面披露了信息披露义务人在成都市贝瑞和康基因技术股份 ...